Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Eur Urol
; 2024 May 21.
Article
in En
| MEDLINE
| ID: mdl-38777648
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Eur Urol
Year:
2024
Type:
Article
Affiliation country:
United States